Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.68 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352855 | 0.82 | DRD4 (0.52) | SIGMAR1DRD2DRD4 | |
| SCHEMBL6352852 | 0.82 | DRD4 (0.52) | SIGMAR1DRD2DRD4 | |
| SCHEMBL6359982 | 0.78 | SIGMAR1 (0.52) | SIGMAR1DRD2HTR1ADRD4DRD3 | |
| SCHEMBL11783486 | 0.76 | DRD2 (0.61) | SIGMAR1DRD2HTR1AADRA2CDRD4 | |
| SCHEMBL9875807 | 0.73 | SIGMAR1 (0.72) | SIGMAR1DRD2HTR1ATSHR | |
| SCHEMBL11809344 | 0.72 | DRD2 (0.79) | SIGMAR1DRD2HTR1AADRA2CHTR2A | |
| SCHEMBL11793421 | 0.70 | DRD2 (1.00) | SIGMAR1DRD2HTR1AADRA2CDRD4 | |
| SCHEMBL6346741 | 0.70 | ALDH1A1 (0.46) | SIGMAR1DRD2HTR1AADRA2CDRD4 | |
| SCHEMBL9879618 | 0.69 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR1A | |
| SCHEMBL11787803 | 0.69 | DRD2 (0.64) | SIGMAR1DRD2HTR1AADRA2CDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | SIGMAR1 1275/4885DRD2 1704/4885HTR1A 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.